Compound Guide
Ipamorelin / CJC-1295 Research — Synergistic Dual-Axis GH Secretagogue Stack
Editorial Standards
Avera Refined Wellness holds its research journal content to a standard requiring specific research claims to reference published, peer-reviewed sources — not general assertions. We are in the process of auditing and updating existing journal content to consistently meet this standard.
Ipamorelin / CJC-1295: synergistic GH secretagogue stack via dual pituitary receptor activation. Ipamorelin — first selective GHRP (Raun 1998).
All products are supplied strictly for in-vitro laboratory research use only by qualified professionals. Not for human consumption. Not intended to diagnose, treat, cure, or prevent any disease.
The ipamorelin / CJC-1295 No-DAC combination targets two distinct receptors on the same pituitary somatotroph cell via non-overlapping intracellular signaling pathways, producing synergistic GH release significantly greater than either compound alone.
Ipamorelin — First Selective GH Secretagogue
Ipamorelin (Aib-His-D-2-Nal-D-Phe-Lys-NH₂) was characterized by Raun K et al. (Eur J Endocrinol. 1998;139:552–561) as the first selective growth hormone secretagogue. Versus earlier GHRPs, ipamorelin achieves equivalent GH release while producing less than one-third the cortisol elevation and statistically negligible prolactin changes. It does not stimulate appetite or cardiovascular GHS-R splice variants at standard research doses.
CJC-1295 No-DAC — Human Trial Data
CJC-1295 No-DAC (Modified GRF 1-29) comprises the first 29 amino acids of GHRH with four stabilizing amino acid substitutions. The Teichman SL et al. human Phase 1/2 trial (J Clin Endocrinol Metab. 2006;91(3):799–805, PMID: 16352683) demonstrated dose-dependent increases in mean plasma GH concentrations of 2- to 10-fold for 6+ days and IGF-1 elevations of 1.5- to 3-fold lasting 9–11 days following a single subcutaneous dose of CJC-1295. The study used the with-DAC formulation; No-DAC has a substantially shorter half-life and more pulsatile profile.
GHRH + GHRP Synergy
In vivo, GHRH and GHRP-class peptides show striking synergistic action on GH release: the combined administration of a GHRH analog and a GHS-R1a agonist produces GH release significantly greater than the arithmetical sum of each compound individually. This is documented across multiple studies (Micle I et al., Clin Endocrinol, 1995; reviewed in Giustina A, Veldhuis JD, Endocr Rev, 1998) and is attributed to simultaneous activation of the cAMP-dependent GHRH receptor pathway and the calcium-dependent GHS-R1a pathway on the same somatotroph cell.
Key References
- Raun K, et al. Ipamorelin, the first selective GH secretagogue. Eur J Endocrinol. 1998;139:552–561.
- Teichman SL, et al. Prolonged stimulation of GH and IGF-1 by CJC-1295. J Clin Endocrinol Metab. 2006;91(3):799–805. PMID: 16352683.
- Ionescu M, Frohman LA. Pulsatile GH secretion persists during continuous CJC-1295 stimulation. J Clin Endocrinol Metab. 2006;91(12):4792–4797. PMID: 17018654.
- Giustina A, Veldhuis JD. Pathophysiology of the neuroregulation of GH secretion in experimental animals and the human. Endocr Rev. 1998;19(6):717–797.
For educational and research reference only. Ipamorelin/CJC-1295 are supplied for in-vitro laboratory research use only. Not for human consumption.
Compounds Referenced in This Article
For in-vitro laboratory research use only
Research Disclaimer: All content published in the Avera Research Journal is provided for informational and scientific discussion purposes only. It does not constitute medical advice, treatment guidance, or a recommendation for human use of any compound. All Avera products are supplied exclusively for in-vitro laboratory research by qualified professionals. Not FDA-evaluated. Not for human consumption.
This article is for informational and research purposes only. All compounds referenced are sold strictly for in-vitro laboratory research use and are not intended for human consumption, veterinary use, or clinical/diagnostic procedures. These statements have not been evaluated by the FDA. Avera Refined Wellness is a subsidiary of RDS 412 LLC.
Related Research